Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Alessandro ParisiAlessio CortelliniKatia CannitaOlga VendittiFloriana CamardaMaria Alessandra CalegariLisa SalvatoreGiampaolo TortoraDaniele RossiniMarco Maria GermaniAlessandra BoccaccinoEmanuela Dell'AquilaClaudia FulgenziDaniele SantiniMichele De TursiNicola TinariPietro Di MarinoPasquale LombardiSusana Roselló KeränenMarisol Huerta ÁlvaroIna Valeria ZurloDomenico Cristiano CorsiAlessandra EmilianiNicoletta ZanalettiTeresa TroianiPasquale VitaleRiccardo GiampieriFilippo MerloniMario Alberto OcchipintiPaolo MarchettiMichela RobertoFederica MazzucaMichele GhidiniAlice IndiniIngrid GarajovaFederica ZorattoSimona Delle MonacheGiampiero PorzioCorrado FicorellaPublished in: Cancers (2020)
Our analysis seems to reveal that Bevacizumab-based regimens have a slightly better PFS and class-specific AEs profile compared to Aflibercept-based regimen as second-line treatment of RAS wild-type mCRC patients previously treated with anti-EGFR based treatments. These results have to be taken with caution and no conclusive considerations are allowed.
Keyphrases
- wild type
- metastatic colorectal cancer
- small cell lung cancer
- end stage renal disease
- epidermal growth factor receptor
- newly diagnosed
- tyrosine kinase
- ejection fraction
- chronic kidney disease
- genome wide
- endothelial cells
- vascular endothelial growth factor
- cross sectional
- clinical trial
- dna methylation
- combination therapy
- cell therapy
- double blind
- age related macular degeneration